NASDAQ: XENEXenon Pharmaceuticals Inc Stock
$39.88-0.43 (-1.07%)
Updated Apr 19, 2024
XENE Price
$39.88
Fair Value Price
$2.06
Market Cap
$3.01B
52 Week Low
$27.99
52 Week High
$50.99
P/E
-14.61x
P/B
3.24x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$182.39M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.04
Operating Cash Flow
-$145M
Beta
0.81
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
XENE Overview
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how XENE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XENE ($39.88) is overvalued by 1,836.64% relative to our estimate of its Fair Value price of $2.06 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
XENE ($39.88) is not significantly undervalued (1,836.64%) relative to our estimate of its Fair Value price of $2.06 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
XENE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more XENE due diligence checks available for Premium users.
Be the first to know about important XENE news, forecast changes, insider trades & much more!
XENE News
Valuation
XENE fair value
Fair Value of XENE stock based on Discounted Cash Flow (DCF)
Price
$39.88
Fair Value
$2.06
Overvalued by
1,836.64%
XENE ($39.88) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
XENE ($39.88) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
XENE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
XENE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-14.61x
Industry
15.81x
Market
40.51x
XENE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.24x
Industry
5.74x
XENE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
XENE's financial health
Profit margin
Revenue
$0.0
Net Income
-$44.7M
Profit Margin
0%
XENE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$964.8M
Liabilities
$36.9M
Debt to equity
0.04
XENE's short-term assets ($644.96M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XENE's short-term assets ($644.96M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XENE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
XENE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$35.5M
Investing
-$239.7M
Financing
$324.0M
XENE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
XENE vs Biotech Stocks
Xenon Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.